- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02419859
A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus
July 25, 2016 updated by: CeQur Corporation
A Prospective, Single Center Study to Assess the Performance, Safety, and Patient Reported Outcomes of Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, single center, open-label, uncontrolled study to assess the efficacy, safety, and patient reported outcomes of insulin delivery with PaQ® in patients with type 2 diabetes mellitus (T2DM) who are currently receiving basal/bolus insulin therapy with or without oral anti-diabetic drugs (OADs) for glycemic control.
The patient's participation in the study is comprised of three phases: screening/baseline evaluation, transition to PaQ use and optimization, and PaQ treatment period.
The use of these phases will allow an orderly transition to PaQ treatment as well as a reliable construct from which to interpret the final data.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Graz, Austria, A-8036
- Medical University of Graz
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Is at least 18 years of age;
- Has a clinical diagnosis of T2DM, as determined by clinical history and medication usage;
- Has an A1C ≥ 7.0% and ≤ 11.0%;
- Is treated with basal-bolus insulin therapy (at least 2 injections per day) with or without OADs, and/or GLP-1 agonist for at least 3 months and has not had a change (addition or discontinuation of existing drug or change in dose) in their OADs for the last 8 weeks, (See Section 7.4 for definition of baseline basal bolus therapy);
- Determined by the investigator that insulin requirements to achieve glycemic targets can be met by the insulin capacity of the PaQ device;
- If on concomitant metformin, has serum creatinine <1.5 mg/dL (male) or <1.4 mg/dL (female);
- If female, and of child-bearing potential, has a negative urine pregnancy test at screening and must be using adequate means of contraception as determined by the Investigator;
- Is clinically euthyroid as judged by the Investigator;
- Is able to understand and sign the required study documents and comply with the CIP requirements;
- Is deemed capable by the Investigator to perform the requirements of the CIP, including use of PaQ, frequent self-monitoring of blood glucose.
Exclusion Criteria:
- Is poorly compliant with the currently prescribed diabetes regimen, as determined by the Investigator;
- Is poorly compliant with prescribed self-monitoring of blood glucose, as determined by the Investigator;
- Is currently taking or has taken sulfonylureas within the last 2 months;
- Has a BMI greater than 40 kg/m2;
- Has experienced recurrent severe hypoglycemia (> 2 episodes) requiring assistance during the past 6 months;
- Has existing dermal irritation/inflammation over the abdominal area that may interfere with use of PaQ, as determined by the Investigator;
- Has known clinically significant hypersensitivity to skin adhesives;
- Is female and if of child-bearing potential, is pregnant, lactating, or planning to become pregnant;
- Is currently being treated with or expected to require or undergo treatment with systemic steroids by oral, intravenous, or intramuscular route (inhaled with low systemic exposure is permitted);
- Currently abuses drugs or alcohol or has a history of abuse that in the Investigator's opinion would cause the individual to be non-compliant;
- Has received any investigational drug within 1 month;
- Has donated blood within 30 days;
- Has any significant medical condition (including current or past history of cardiovascular disease), laboratory findings, or medical history that in the Investigator's opinion may affect successful completion of the study and/or personal well-being;
- Is an immediate family member (spouse, parent, child, or sibling) of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PaQ® Insulin Delivery Device
The intervention is continuous subcutaneous U 100 Insulin, Asp(B28)-rapid-acting insulin, at a constant basal rate of either 20, 24, 32, 40 or 50 U per day over 3 days and and bolus insulin as needed at meals in 2 U increments.
|
PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin.
Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
a fast-acting analog of human insulin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood)
Time Frame: Change from Baseline at 12 weeks
|
Change from Baseline at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood)
Time Frame: Change from Baseline at 8 weeks
|
Change from Baseline at 8 weeks
|
|
Fasting plasma glucose
Time Frame: Change from Baseline at 12 weeks
|
Change from Baseline at 12 weeks
|
|
7-point blood glucose profiles
Time Frame: Change from Baseline at 12 weeks
|
Change from Baseline at 12 weeks
|
|
Total daily dose of insulin
Time Frame: Change from Baseline at 12 weeks
|
Change from Baseline at 12 weeks
|
|
Body weight
Time Frame: Change from Baseline at 12 weeks
|
Change from Baseline at 12 weeks
|
|
Barriers to Insulin Treatment questionnaire
Time Frame: Change from Baseline at 12 weeks
|
Measures aspects of psychological obstacles to insulin treatment in people with type 2 diabetes.
|
Change from Baseline at 12 weeks
|
Diabetes Treatment Satisfaction Questionnaire
Time Frame: Change from Baseline at 12 weeks
|
Designed to make the initial assessment of total diabetes treatment satisfaction, treatment satisfaction in specific areas, and perceived frequencies of hyperglycemia and hypoglycemia.
|
Change from Baseline at 12 weeks
|
Short form 36 Health Survey
Time Frame: Change from Baseline at 12 weeks
|
It is a generic measure, as opposed to disease specific, which assesses the relative burden of diseases, and differentiates the health benefits produced by a wide range of different treatments.
|
Change from Baseline at 12 weeks
|
Adverse events
Time Frame: Collected throughout the study, average 14 weeks
|
Collected throughout the study, average 14 weeks
|
|
Hypoglycemic events
Time Frame: Collected at baseline (on current insulin therapy) and throughout the study, average 14 weeks
|
Collected at baseline (on current insulin therapy) and throughout the study, average 14 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
March 24, 2015
First Submitted That Met QC Criteria
April 14, 2015
First Posted (Estimate)
April 17, 2015
Study Record Updates
Last Update Posted (Estimate)
July 26, 2016
Last Update Submitted That Met QC Criteria
July 25, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CQR14002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
No plan to share individual data sets, but will publish the results.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaRecruiting
Clinical Trials on PaQ® Insulin Delivery Device
-
CeQur CorporationTerminatedType 2 Diabetes MellitusAustria
-
CeQur CorporationInternational Diabetes Center at Park NicolletCompletedType 2 Diabetes MellitusAustria
-
Wake Forest University Health SciencesNot yet recruitingCognitive Impairment | Mild Cognitive Impairment | Alzheimer Disease, Early Onset
-
Cerenovus, Part of DePuy Synthes Products, Inc.TerminatedIntracranial AneurysmUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesBrazil
-
SanofiCompletedType 2 DiabetesUnited States, Canada, Chile, Czech Republic, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
-
Wake Forest University Health SciencesRecruitingCognitive Impairment | Alzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Norfolk and Norwich University Hospitals NHS Foundation...King's College London; University of Leeds; Belfast Health and Social Care Trust and other collaboratorsCompletedDiabetesUnited Kingdom
-
RxSight, Inc.Completed